Preclinical Assets Market Analysis: Major Players, Lucrative Segments And Top Geographies
29 Nov, 2023
The global preclinical assets market is expected to grow from $4.84 billion in 2022 to $5.32 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The preclinical assets market is expected to reach $7.62 billion in 2027 at a CAGR of 9.4%.
Global Preclinical Assets Market Key Driver
Increasing drug discovery is expected to drive the growth of the preclinical asset market in the coming years. Drug discovery is the process of identifying chemical substances suitable for use as medicinal agents, crucial in discovering new candidate medications. Within this process, preclinical assets play a vital role by providing essential data and evidence to assist in the selection of molecules for clinical development.
Get a sample of the global preclinical assets market reportGlobal Preclinical Assets Market Segments
The global preclinical assets market is segmented:
1) By Service: Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users
4) By Geography: The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global preclinical assets market.
Major Preclinical Assets Industry Players
Preclinical Assets Market Overview
A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals.
Preclinical Assets Global Market Report 2023 provides data on the global preclinical assets market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The preclinical assets market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.